Cargando…
Antipsychotic treatments; focus on lurasidone
The introduction of atypical antipsychotic drugs (AAPDs), or second-generation antipsychotics, with clozapine as the prototype, has largely changed the clinicians' attitudes toward the treatment of mental illnesses including, but not limited to schizophrenia. Initially, there was optimism that...
Autor principal: | Sumiyoshi, Tomiki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753015/ https://www.ncbi.nlm.nih.gov/pubmed/23986702 http://dx.doi.org/10.3389/fphar.2013.00102 |
Ejemplares similares
-
Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression
por: Loebel, Antony, et al.
Publicado: (2015) -
Neutropenia with Multiple Antipsychotics Including Dose Dependent Neutropenia with Lurasidone
por: Sood, Shabnam
Publicado: (2017) -
Dose Reduction/Discontinuation of Antipsychotic Drugs in Psychosis; Effect on Cognition and Functional Outcomes
por: Omachi, Yoshie, et al.
Publicado: (2018) -
Serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia
por: Sumiyoshi, Tomiki, et al.
Publicado: (2014) -
Neural Basis for the Ability of Atypical Antipsychotic Drugs to Improve Cognition in Schizophrenia
por: Sumiyoshi, Tomiki, et al.
Publicado: (2013)